Can You Take Levothyroxine and Warfarin Together?

Yes, levothyroxine and warfarin can be used together, and this combination is frequently prescribed in clinical practice. However, levothyroxine can indirectly affect how warfarin works in your body, requiring closer monitoring and potential dose adjustments of warfarin to maintain safe anticoagulation levels.

What the FDA Says

Neither the levothyroxine nor the warfarin FDA-approved drug labels list the other as a contraindicated medication, meaning the drugs are not absolutely forbidden from being used together. However, both drug labels contain important clinical guidance relevant to this combination.

The warfarin (coumarin) drug label acknowledges that thyroid hormone replacement therapy can potentiate the anticoagulant effect of warfarin. This means that levothyroxine can amplify warfarin's blood-thinning action, increasing the risk of bleeding if warfarin doses are not properly adjusted. The levothyroxine label, conversely, does not specifically mention warfarin but does note that thyroid hormones increase the metabolic rate of the body, which can affect how other medications work.

The FDA advises that patients on warfarin who require thyroid replacement therapy need frequent International Normalized Ratio (INR) monitoring—particularly when levothyroxine is started, when doses are changed, or when thyroid function status changes. This is a recognized and manageable clinical scenario, not an absolute contraindication.

How This Interaction Works

The interaction between levothyroxine and warfarin is indirect but clinically significant. Understanding the mechanism helps explain why monitoring is essential.

Thyroid Hormone and Metabolism: Levothyroxine is the synthetic form of thyroxine (T4), a thyroid hormone that regulates metabolic rate. When levothyroxine levels increase in the bloodstream—either because a patient is being newly treated for hypothyroidism or because their dose is increased—the overall metabolic rate of the body increases. This elevation in metabolic rate affects drug clearance (elimination) from the body.

Warfarin Metabolism: Warfarin is metabolized primarily by the cytochrome P450 enzyme system, particularly by CYP2C9 and CYP3A4. Warfarin also undergoes hepatic metabolism and requires vitamin K-dependent clotting factor synthesis to exert its anticoagulant effect. When thyroid hormone levels are low (hypothyroidism), metabolic processes slow down, including warfarin clearance. Conversely, when thyroid hormone levels are high or increased through levothyroxine supplementation, warfarin is cleared more rapidly from the body.

The Net Clinical Effect: This is where the interaction becomes counterintuitive. You might expect that faster warfarin clearance would reduce its anticoagulant effect, requiring a higher warfarin dose. However, the clinical reality is more complex. Elevated thyroid hormone levels also increase the metabolic rate of clotting factor synthesis, reducing vitamin K-dependent clotting factors (II, VII, IX, X)—the very targets of warfarin inhibition. This means that adequate thyroid hormone actually enhances warfarin's anticoagulant effect at the tissue level, even while increasing warfarin clearance from plasma. The net result is potentiation of warfarin's effect, requiring warfarin dose reduction in many patients.

Stability of Thyroid Function: The interaction is most clinically relevant during periods of thyroid function instability—when levothyroxine doses are being initiated or adjusted. Once a stable levothyroxine dose is established and thyroid function is normalized (TSH in target range), the interaction typically stabilizes, though ongoing monitoring remains important.

Who Is Most at Risk

Certain patient populations face higher risk from this interaction:

• Patients starting levothyroxine therapy: Those newly diagnosed with hypothyroidism and beginning levothyroxine treatment while already on warfarin are at elevated risk of INR elevation and bleeding.
• Patients with dose adjustments: Any change in levothyroxine dosing—increases or decreases—can destabilize the warfarin-thyroid hormone balance.
• Older adults (age 65+): Elderly patients on warfarin are already at higher baseline bleeding risk and may be more sensitive to INR fluctuations.
• Patients with renal or hepatic disease: Impaired organ function slows drug clearance and increases interaction severity.
• Patients with atrial fibrillation requiring both drugs: This is a common clinical scenario where thyroid disease and afib may coexist.
• Patients with unstable thyroid disease: Those with fluctuating TSH levels or conditions like thyroiditis experience more variable thyroid hormone levels, making INR control more difficult.
• Patients on higher warfarin doses: Those requiring 7.5 mg daily or more are at higher bleeding risk if INR escalates.

Two Clinical Scenarios

Scenario 1: New Levothyroxine Therapy in a Stable Warfarin Patient

Margaret is a 72-year-old woman with a 3-year history of atrial fibrillation, stable on warfarin 6 mg daily with an INR of 2.2 (target 2.0–3.0). Her recent TSH comes back at 8.5 mIU/L, indicating hypothyroidism. Her physician starts levothyroxine 25 mcg daily. Without close monitoring, Margaret's INR could begin to drift upward over the next 2–3 weeks as levothyroxine becomes active. If unchecked, her INR might reach 3.5 or higher, increasing bleeding risk. However, with her physician and pharmacist aware of the interaction, they schedule INR checks at 1 week, 2 weeks, and 4 weeks post-initiation. By week 3, her INR has risen to 2.8. Her warfarin dose is reduced to 5.5 mg daily. Subsequent checks confirm INR stability around 2.3. The key is proactive monitoring, not avoidance of levothyroxine.

Scenario 2: Levothyroxine Dose Increase in a Stable Patient

James is a 58-year-old man on stable levothyroxine 75 mcg daily (TSH 2.1) and warfarin 5 mg daily (INR 2.4). He develops symptoms of hypothyroidism and his TSH rises to 6.8. His endocrinologist increases levothyroxine to 100 mcg daily. James's pharmacist flags this change and recommends an INR check in 7–10 days. When checked, his INR is 3.1—above the target of 2.0–2.5. His warfarin is reduced to 4.5 mg daily. A recheck in 2 weeks confirms INR back to 2.2. Again, the interaction was managed through communication and monitoring, not by avoiding either drug.

What to Do: Management Strategies

For Patients:

• Inform all healthcare providers that you take both levothyroxine and warfarin. Use a medication list or app to track both drugs.
• Do not miss levothyroxine doses or take extra doses without instructions. Consistency is essential for warfarin stability.
• Take levothyroxine on an empty stomach, 30–60 minutes before breakfast, to optimize absorption. Do not take with calcium, iron, or antacids, as these can reduce levothyroxine absorption and cause unpredictable INR effects.
• Keep INR monitoring appointments. Your physician will likely schedule checks at 1–2 weeks after any levothyroxine change, then monthly or quarterly once stable.
• Report any signs of bleeding (see section below) immediately.
• Do not start or stop any new medications, supplements, or over-the-counter drugs without consulting your pharmacist first, as many can interact with both levothyroxine and warfarin.

For Healthcare Providers and Pharmacists:

• At baseline, assess thyroid function (TSH, free T4) in all warfarin patients and document current INR stability.
• When initiating levothyroxine in a warfarin patient, use conservative starting doses (25 mcg) and plan for frequent INR monitoring (baseline, 1 week, 2 weeks, 4 weeks, then as needed).
• When adjusting levothyroxine doses, anticipate potential INR changes and schedule follow-up INR testing within 7–10 days.
• Consider more frequent monitoring in high-risk populations (elderly, renal/hepatic disease, high warfarin doses).
• Educate patients on consistent levothyroxine administration and the importance of INR monitoring.
• Document the interaction in the patient's chart and flag it in electronic health records (EHR) to alert other providers.

When to Call Your Doctor or Pharmacist

Contact your healthcare provider immediately or seek emergency care if you experience:

• Unusual bruising or bleeding (nosebleeds, bleeding gums, blood in urine or stool, coughing up blood)
• Severe headache, confusion, or difficulty concentrating
• Abdominal pain or distension (suggests internal bleeding)
• Black or tarry stools
• Heavy menstrual bleeding (in women)
• Joint pain or swelling with no clear cause
• Shortness of breath or chest pain

Contact your doctor or pharmacist within 24 hours if you:

• Miss a dose of levothyroxine or warfarin
• Accidentally take a double dose of either medication
• Start a new medication, supplement, or herbal product
• Develop symptoms of hyper- or hypothyroidism (fatigue, weight changes, palpitations, heat or cold intolerance)
• Are scheduled for surgery or a procedure
• Have a significant illness or fever

Key Takeaways

• Levothyroxine and warfarin can be safely used together but require close INR monitoring, especially when levothyroxine is started or doses are adjusted.
• The interaction is indirect: Levothyroxine increases metabolic rate and enhances warfarin's anticoagulant effect, potentially requiring warfarin dose reduction.
• Timing matters: Increased INR risk is highest during the first 2–4 weeks after levothyroxine initiation or dose change; plan for frequent INR checks during these periods.
• Consistency is essential: Take levothyroxine at the same time every day on an empty stomach, and do not change doses without medical guidance.
• Communication is critical: Ensure all your doctors and pharmacists know you take both drugs, and report any signs of bleeding or symptoms of thyroid dysfunction immediately.

Sources

• FDA Drug Labeling via OpenFDA: open.fda.gov (warfarin sodium and levothyroxine sodium labels)
• National Library of Medicine, PubMed: pubmed.ncbi.nlm.nih.gov
• American College of Chest Physicians (ACCP) Guidelines on Antithrombotic Therapy
• Endocrine Society Clinical Practice Guidelines for Hypothyroidism
• FDA Warfarin Labeling: FDA CDER Approved Drug Labels

More interactions to explore: Learn how warfarin and aspirin interact, or check levothyroxine and calcium together. For a comprehensive review of all your medications, visit checkdruginteractions.com and enter your full medication list. Our FDA-powered interaction checker provides personalized insights based on over 250,000 drug labels and can help you and your pharmacist identify risks you might otherwise miss.